Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

EJNMMI Research

Table 4 Comparison of patient clinical data with TMTV and TLG

Variable	No. of patients (n = 84)	TMTV			TLG
Variable	No. of patients (n = 84)	Low (n = 43)	High (n = 41)	P value*	Low (n = 35)	High (n = 49)	P value*
Sex, F/M	30/54	15/28	15/26	1.000	14/21	16/33	0.499
Age, ≤ 60/> 60	43/41	25/18	18/23	0.275	21/14	22/27	0.191
LDH level, normal/elevated	38/46	24/19	14/27	0.052	21/14	17/32	0.027
B symptoms, no/yes	33/51	23/20	10/31	0.008	18/17	15/34	0.071
ECOG PS, 0–1/ ≥ 2	57/27	35/8	22/19	0.010	28/7	29/20	0.059
Ann Arbor stage, I–II/III–IV	15/69	11/32	4/37	0.087	10/25	5/44	0.043
Extranodal sites ≥ 2, no/yes	65/19	36/7	29/12	0.196	29/6	36/13	0.429
BMB, negative/positive	63/21	36/7	27/14	0.079	28/7	35/14	0.449
Ki-67 ≥ 80%, no/yes	60/24	33/10	27/14	0.336	26/9	34/15	0.807
Platelet cell count, ≥ 150 × 10⁹/L	48/36	24/19	24/17	0.829	22/13	26/23	0.503
IPI, 0–2/3–5	47/37	34/9	13/28	< 0.001	27/8	20/29	0.002
PIT, 0–1/2–4	41/43	29/14	12/29	0.001	24/11	17/32	0.004
IPTCLP, 0–1/2, 3	54/30	31/12	23/18	0.172	26/9	28/21	0.165

A chi-square test was used to test the significance of the association between clinical data and the baseline TMTV and TLG
LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, MTV metabolic tumor volume, TLG total lesion glycolysis
*P < 0.05